• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Stepan Reports Fourth Quarter 2024 Results

    2/19/25 7:00:00 AM ET
    $SCL
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $SCL alert in real time by email

    NORTHBROOK, Ill., Feb. 19, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported:

    Stepan Company Logo (PRNewsfoto/Stepan Company)

    Fourth Quarter 2024 Highlights

    • Reported net income was $3.4 million versus a $1.2 million net loss in the prior year. Adjusted net income(1) was $2.8 million, down 63% versus prior year, largely due to higher pre-commissioning expenses at our new alkoxylation investment in Pasadena, Texas ($4.4 million increase), a one-time tax proceeding reserve of $2.9 million recorded in our Latin American operations and higher expenses associated with the previously announced CEO transition in the fourth quarter of 2024.
    • EBITDA(2) was $35.8 million and Adjusted EBITDA(2) was $35.0 million, up 39% and down 7% respectively, year-over-year.
    • Global sales volume was down 1% year-over-year. Double digit growth in several Surfactant end markets was fully offset by demand weakness in Polymers.
    • Cash from Operations was $68.3 million during the quarter. Free cash flow(3) for the quarter was $32.1 million.
    • The Company delivered $13.0 million in pre-tax cost out savings in the fourth quarter of 2024.

    YTD 2024 Highlights

    • Reported net income was $50.4 million, up 25% versus prior year. Adjusted net income(1) was $50.5 million, flat versus prior year.
    • EBITDA(2) was $186.9 million and Adjusted EBITDA(2) was $187.0 million, up 13% and 4% respectively, year-over-year.
    • Global sales volume was up 1% year-over-year.
    • Free cash flow(3) for the year was $39.3 million versus a negative $85.5 million in the prior year.
    • The Company delivered $48.0 million in cost out savings for 2024 despite significant one-time extra costs, including higher operating costs at our Millsdale site, primarily related to a flood event during the first half of 2024, and higher costs related to a criminal fraud event at a subsidiary in Asia.

    "While we are disappointed with our overall financial performance in 2024, we advanced our strategic investments and took necessary steps to return the Company to profitable growth.  I am proud of the resilience, hard work and dedication of the entire organization.  Full year Adjusted EBITDA grew 4% versus prior year despite several one-time events that negatively impacted earnings and the pre-operating expenses in our new Pasadena, site," said Luis E. Rojo, President and Chief Executive Officer.  "Surfactants and Specialty Products delivered strong double-digit Adjusted EBITDA growth, partially offset by demand weakness in Polymers.  Overall, global sales volume grew 1%, driven by 2.5% growth in our Surfactant business.  We are encouraged by the Surfactant growth within several of our key strategic end markets.  We delivered $39 million of free cash flow, which was in line with our expectations, and we increased our dividend for the 57th consecutive year.  We completed the majority of our new Pasadena, Texas site which is critical to growing our alkoxylation business.  Our strong foundation, combined with the cost reductions and strategic investments we have made, position us well to deliver future growth."

    Financial Summary





    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,



    ($ in thousands, except per share data)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Net Sales



    $

    525,609





    $

    532,131







    (1)

    %



    $

    2,180,274





    $

    2,325,768







    (6)

    %

    Operating Income



    $

    7,695





    $

    230





    NM





    $

    70,480





    $

    58,613







    20

    %

    Net Income



    $

    3,350





    $

    (1,193)





    NM





    $

    50,370





    $

    40,204







    25

    %

    Earnings per Diluted Share



    $

    0.15





    $

    (0.05)





    NM





    $

    2.20





    $

    1.75







    26

    %







































    Adjusted Net Income *



    $

    2,757





    $

    7,485







    (63)

    %



    $

    50,470





    $

    50,692







    (0)

    %

    Adjusted Earnings per

       Diluted Share *



    $

    0.12





    $

    0.33







    (64)

    %



    $

    2.20





    $

    2.21







    (0)

    %





    * See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.







    Percentage Change in Net Sales

    Net sales in the fourth quarter of 2024 decreased 1% year-over-year.  This slight decrease reflects higher selling prices that were more than offset by a 1% decline in sales volume and the negative impact of foreign currency translation. 





    Three Months Ended

    December 31, 2024





    Twelve Months Ended

    December 31, 2024



    Volume





    (1)

    %





    1

    %

    Selling Price & Mix





    2

    %





    (7)

    %

    Foreign Translation





    (2)

    %





    (—)

    %

    Total





    (1)

    %





    (6)

    %



    Segment Results





    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,



    ($ in thousands)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Net Sales





































    Surfactants



    $

    378,776





    $

    369,468







    3

    %



    $

    1,532,115





    $

    1,602,819







    (4)

    %

    Polymers



    $

    129,844





    $

    147,271







    (12)

    %



    $

    584,905





    $

    642,471







    (9)

    %

    Specialty Products



    $

    16,989





    $

    15,392







    10

    %



    $

    63,254





    $

    80,478







    (21)

    %

    Total Net Sales



    $

    525,609





    $

    532,131







    (1)

    %



    $

    2,180,274





    $

    2,325,768







    (6)

    %

     





    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,



    ($ in thousands, all amounts pre-tax)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Operating Income





































    Surfactants



    $

    16,173





    $

    14,830







    9

    %



    $

    85,618





    $

    72,399







    18

    %

    Polymers



    $

    3,396





    $

    12,632







    (73)

    %



    $

    40,623





    $

    60,770







    (33)

    %

    Specialty Products



    $

    5,594





    $

    2,773







    102

    %



    $

    20,908





    $

    11,476







    82

    %

    Total Segment

       Operating Income



    $

    25,163





    $

    30,235







    (17)

    %



    $

    147,149





    $

    144,645







    2

    %

    Corporate Expenses



    $

    (17,468)





    $

    (30,005)







    (42)

    %



    $

    (76,669)





    $

    (86,032)







    (11)

    %

    Consolidated

       Operating Income



    $

    7,695





    $

    230







    3,246

    %



    $

    70,480





    $

    58,613







    20

    %

     





    Three Months Ended

    December 31,





    Year Ended

    December 31,



    ($ in millions)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    EBITDA



    $

    35.8





    $

    25.8







    39

    %



    $

    186.9





    $

    165.8







    13

    %







































    Adjusted EBITDA





































       Surfactants



    $

    34.7





    $

    31.6







    10

    %



    $

    157.6





    $

    136.7







    15

    %

       Polymers



    $

    11.4





    $

    20.5







    (44)

    %



    $

    73.0





    $

    93.2







    (22)

    %

       Specialty Products



    $

    7.1





    $

    4.3







    65

    %



    $

    26.9





    $

    17.3







    55

    %

       Unallocated Corporate



    $

    (18.2)





    $

    (18.9)







    (4)

    %



    $

    (70.5)





    $

    (67.2)







    5

    %

    Consolidated Adjusted EBITDA



    $

    35.0





    $

    37.5







    (7)

    %



    $

    187.0





    $

    180.0







    4

    %





    Consolidated operating income in the quarter increased $7.5 million year-over-year.  Consolidated adjusted EBITDA(2) decreased $2.5 million, or 7%, year-over-year largely due to the demand shortfall in Polymers and higher expenses associated with the Latin American tax proceeding reserve and the previously announced fourth quarter CEO transition.    

    • Surfactant net sales were $378.8 million for the quarter, a 3% increase versus the prior year. Selling prices were up 5% primarily due to improved product and customer mix. Sales volume was up 1% year-over-year primarily due to double digit growth within the Agricultural and Oilfield end markets along with our distribution partners. This growth was partially offset by lower demand within the Consumer Products end markets. Foreign currency translation negatively impacted net sales by 3%. Surfactant operating income for the quarter increased $1.3 million, or 9%, versus the prior year. Surfactant adjusted EBITDA(2) increased $3.1 million, or 10%, versus the prior year. This increase was primarily driven by the 1% growth in sales volume and slight margin improvement, partially offset by pre-operating expenses at the Company's new alkoxylation facility being built in Pasadena, Texas and the tax proceeding reserve recognized in Latin American operations.



    • Polymer net sales were $129.8 million for the quarter, a 12% decrease versus the prior year. Selling prices decreased 4%, primarily due to the pass-through of lower raw material costs and competitive pressures. Sales volume declined 9% in the quarter primarily due to an 11% decrease in global Rigid Polyols demand. Specialty Polyols volume was up year-over-year. Foreign currency translation positively impacted net sales by 1%. Polymer operating income decreased $9.2 million, or 73%, versus the prior year. Polymer adjusted EBITDA(2) decreased $9.1 million, or 44%, versus the prior year primarily due to the 9% decline in sales volume.



    • Specialty Product net sales were $17.0 million for the quarter, a 10% increase versus the prior year, primarily due to higher sales volume and higher selling prices. Sales volume was up 32% versus the prior year. Specialty Product operating income increased $2.8 million, or 102%, versus the prior year. Specialty Product adjusted EBITDA(2) increased $2.8 million, or 65%. The increase in adjusted EBITDA(2) was primarily due to margin recovery and higher sales volume within the medium chain triglycerides product line.

    Income Taxes

    The Company's full year effective tax rate was 16.7% in 2024 versus 16.9% in 2023.  This small decrease was comprised of various offsetting items, most notably a favorable non-recurring deferred tax adjustment in 2024 that offset an unfavorable foreign rate differential in 2024. 

    Outlook

    "As we look forward to 2025, I am excited and energized to continue our focus on accelerating our business strategies through improved execution to drive consistent volume growth, margin improvement and free cash flow generation.  We believe Adjusted EBITDA will improve in all of our reporting segments.  The Stepan Team is executing on opportunities to grow volume, deliver improved product and customer mix and further progress our cost out and cost avoidance initiatives.  We are optimistic that Polymer demand will increase as we execute our innovation and growth plans.  We believe our Surfactant business will experience continued growth in our key strategic end markets," said Luis E. Rojo, President and Chief Executive Officer.  "As previously announced, we expect our Pasadena facility will start up in the first quarter of 2025 and enable us to deliver volume growth and Supply Chain savings during the year.  We believe we are positioned well to deliver full year Adjusted EBITDA and Adjusted Net Income growth and positive free cash flow in 2025."

    Notes





    (1)

    Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, cash-settled stock appreciation rights (SARs) income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.





    (2)

    EBITDA and adjusted EBITDA are non-GAAP measures.  See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA.





    (3)

    Free cash flow is a non-GAAP measure and reflects cash generated from operations minus capital expenditures.  Cash generated from operations was $68.3 million during the fourth quarter of 2024 and capital expenditures were $36.2 million.  Cash generated from operations was $162.1 million during the full year 2024 and capital expenditures were $122.8 million.





    Conference Call

    Stepan Company will host a conference call to discuss its second quarter results at 9:00 a.m. ET (8:00 a.m. CT) on February 19, 2025. The call can be accessed by phone and webcast. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN.  To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time.  The webcast can be accessed through the Investors/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.

    Supporting Slides

    Slides supporting this press release will be made available at www.stepan.com through the Investors/Presentations page at approximately the same time as this press release is issued.

    Corporate Profile

    Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection compounds and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.

    Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia. 

    The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com 

    More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com 

    Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.

    There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to  accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants.

    These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

    Tables follow

    Table I



    STEPAN COMPANY

    For the Three and Twelve Months Ended December 31, 2024 and 2023

    (Unaudited – in 000's, except per share data)







    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,







    2024





    2023





    2024





    2023



    Net Sales



    $

    525,609





    $

    532,131





    $

    2,180,274





    $

    2,325,768



    Cost of Sales





    468,913







    465,726







    1,908,060







    2,048,170



    Gross Profit





    56,696







    66,405







    272,214







    277,598



    Operating Expenses:

























    Selling





    11,018







    12,380







    45,628







    48,367



    Administrative





    24,764







    25,070







    98,277







    93,202



    Research, Development and Technical Services





    13,793







    15,319







    55,674







    59,039



    Deferred Compensation Expense (Income)





    (574)







    5,227







    2,155







    4,371









    49,001







    57,996







    201,734







    204,979





























    Goodwill and Other Intangibles Impairment





    -







    2,038







    -







    2,038



    Business Restructuring and Asset Impairment





    -







    6,141







    -







    11,968





























    Operating Income





    7,695







    230







    70,480







    58,613





























    Other Income (Expense):

























    Interest, Net





    (4,829)







    (2,429)







    (14,182)







    (12,103)



    Other, Net





    (410)







    (1,467)







    4,141







    1,881









    (5,239)







    (3,896)







    (10,041)







    (10,222)





























    Income Before Provision for Income Taxes





    2,456







    (3,666)







    60,439







    48,391



    Provision for Income Taxes





    (894)







    (2,473)







    10,069







    8,187



    Net Income





    3,350







    (1,193)







    50,370







    40,204



    Net Income Per Common Share

























    Basic



    $

    0.15





    $

    (0.05)





    $

    2.21





    $

    1.77



    Diluted



    $

    0.15





    $

    (0.05)





    $

    2.20





    $

    1.75



    Shares Used to Compute Net Income Per

       Common Share

























    Basic





    22,841







    22,794







    22,832







    22,777



    Diluted





    22,912







    22,912







    22,931







    22,946



     

    Table II



    Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share*







    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,



    ($ in thousands, except per share amounts)



    2024





    EPS





    2023





    EPS





    2024





    EPS





    2023





    EPS



    Net Income Reported



    $

    3,350





    $

    0.15





    $

    (1,193)





    $

    (0.05)





    $

    50,370





    $

    2.20





    $

    40,204





    $

    1.75





















































    Deferred Compensation

       (Income) Expense



    $

    (762)





    $

    (0.03)





    $

    2,243





    $

    0.10





    $

    (1,805)





    $

    (0.08)





    $

    (551)





    $

    (0.02)



    Business Restructuring and Asset

        Impairment Expense



    $

    -





    $

    -





    $

    4,564





    $

    0.20





    $

    -





    $

    -





    $

    8,929





    $

    0.39



    Goodwill and Other Intangibles

        Impairment Expense



    $

    -





    $

    -





    $

    1,422





    $

    0.06





    $

    -





    $

    -





    $

    1,422





    $

    0.06



    Cash-Settled SARs (Income) Expense



    $

    -





    $

    -





    $

    71





    $

    -





    $

    -





    $

    -





    $

    (74)





    $

    -



    Environmental Remediation

        Expense



    $

    169





    $

    -





    $

    378





    $

    0.02





    $

    1,905





    $

    0.08





    $

    762





    $

    0.03



    Adjusted Net Income



    $

    2,757





    $

    0.12





    $

    7,485





    $

    0.33





    $

    50,470





    $

    2.20





    $

    50,692





    $

    2.21





    * All amounts in this table are presented after-tax



    The Company believes that certain non-GAAP measures, in conjunction with comparable GAAP measures, are useful for evaluating the Company's operating performance and financial condition.  The Company uses this non-GAAP information as an indicator of business performance and evaluates management's effectiveness with specific reference to these indicators.  Management believes that these non-GAAP financial measures provide useful supplemental information because they exclude non-operational items that affect comparability between years.  These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with GAAP and may differ from similarly titled measures presented by other companies.  The Company's Annual Report on Form 10-K for the year ended December 31, 2023 contains additional information regarding the use of non-GAAP financial measures.

    Summary of Fourth Quarter 2024 Adjusted Net Income Items

    Adjusted net income excludes non-operational deferred compensation income/expense, cash-settled SARs income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.

    • Deferred Compensation: The fourth quarter of 2024 reported net income includes $0.8 million of after-tax income versus $2.2 million of after-tax expense in the prior year.



    • Environmental Remediation: The fourth quarter of 2024 reported net income includes $0.2 million of after-tax expense versus $0.4 million of after-tax expense in the prior year.

    Table III



    Reconciliation of Pre-Tax to After-Tax Adjustments



    Management uses the non-GAAP adjusted net income metric to evaluate the Company's operating performance.  Management excludes the items listed in the table below because they are non-operational items.  The cumulative tax effect was calculated using the statutory tax rates for the jurisdictions in which the transactions occurred.







    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,



    ($ in thousands, except per share amounts)



    2024





    EPS





    2023





    EPS





    2024





    EPS





    2023





    EPS



    Pre-Tax Adjustments

















































    Deferred Compensation (Income) Expense



    $

    (1,016)











    $

    2,991











    $

    (2,406)











    $

    (735)









    Business Restructuring and Asset Impairment Expense



    $

    -











    $

    6,141











    $

    -











    $

    11,968









    Goodwill and Other Intangibles Impairment Expense



    $

    -











    $

    2,038











    $

    -











    $

    2,038









    Cash-Settled SARs (Income) Expense



    $

    -











    $

    95











    $

    -











    $

    (98)









    Environmental Remediation Expense



    $

    225











    $

    504











    $

    2,540











    $

    1,017









       Total Pre-Tax Adjustments



    $

    (791)











    $

    11,769











    $

    134











    $

    14,190



























































    Cumulative Tax Effect on Adjustments



    $

    198











    $

    (3,091)











    $

    (34)











    $

    (3,702)



























































    After-Tax Adjustments



    $

    (593)





    $

    (0.03)





    $

    8,678





    $

    0.38





    $

    100





    $

    0.00





    $

    10,488





    $

    0.46





































































     

    Table IV



    Deferred Compensation Plans



    The full effect of the deferred compensation plans on quarterly pre-tax income was $1.0 million of income versus $3.0 million of expense in the prior year.  The quarter-end market prices of Company stock and the impact of deferred compensation on specific income statement line items is summarized below:







    2024





    2023







    12/31





    9/30





    6/30





    3/31





    12/31





    9/30





    6/30





    3/31



    Stepan Company



    $

    64.70





    $

    77.25





    $

    83.96





    $

    90.04





    $

    94.55





    $

    74.97





    $

    95.56





    $

    103.03





































































     





    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,



    ($ in thousands)



    2024





    2023





    2024





    2023



    Deferred Compensation

























    Operating Income (Expense)



    $

    574





    $

    (5,227)





    $

    (2,155)





    $

    (4,371)



    Other, net – Mutual Fund Gain (Loss)





    442







    2,236







    4,561







    5,106



    Total Pre-Tax



    $

    1,016





    $

    (2,991)





    $

    2,406





    $

    735



    Total After-Tax



    $

    762





    $

    (2,243)





    $

    1,805





    $

    551



     

    Effects of Foreign Currency Translation



    The Company's foreign subsidiaries transact business and report financial results in their respective local currencies. These results are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period.  The table below presents the impact that foreign currency translation had on select income statement line items. 



    ($ in millions)



    Three Months Ended

    December 31,





    Change





    Change

    Due to

    Foreign

    Currency

    Translation





    Twelve Months Ended

    December 31,





    Change





    Change

    Due to

    Foreign

    Currency

    Translation







    2024





    2023

















    2024





    2023















    Net Sales



    $

    525.6





    $

    532.1





    $

    (6.5)





    $

    (9.6)





    $

    2,180.3





    $

    2,325.8





    $

    (145.5)





    $

    (2.5)



    Gross Profit





    56.7







    66.4





    $

    (9.7)







    (1.1)







    272.2







    277.6





    $

    (5.4)







    (1.0)



    Operating Income





    7.7







    0.2





    $

    7.5







    (1.0)







    70.5







    58.6





    $

    11.9







    (0.8)



    Pretax Income





    2.5







    (3.7)





    $

    6.2







    0.2







    60.4







    48.4





    $

    12.0







    0.1



     

    Corporate Expenses







    Three Months Ended

    December 31,





    Twelve Months Ended

    December 31,



    ($ in thousands)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Total Corporate Expenses



    $

    17,468





    $

    30,005







    (42)

    %



    $

    76,669





    $

    86,032







    (11)

    %

    Less:





































       Deferred Compensation (Income) Expense



    $

    (574)





    $

    5,227





    NM





    $

    2,155





    $

    4,371







    (51)

    %

       Business Restructuring and Asset

          Impairment Expense



    $

    -





    $

    6,141







    (100)

    %



    $

    -





    $

    11,968







    (100)

    %

      Goodwill and Other Intangibles

          Impairment Expense



    $

    -





    $

    2,038







    (100)

    %



    $

    -





    $

    2,038







    (100)

    %

       Environmental Remediation

          Expense



    $

    225





    $

    504







    (55)

    %



    $

    2,540





    $

    1,017







    150

    %

    Adjusted Corporate Expenses



    $

    17,817





    $

    16,095







    11

    %



    $

    71,974





    $

    66,638







    8

    %



    Adjusted Corporate expenses increased $1.7 million, or 11% for the quarter. This increase was primarily due to higher expenses associated with the previously announced CEO transition in the fourth quarter of 2024.

    Table V



    Stepan Company

    Consolidated Balance Sheets

    December 31, 2024 and December 31, 2023







    December 31, 2024





    December 31, 2023



    ASSETS













    Current Assets



    $

    810,429





    $

    851,883



    Property, Plant & Equipment, Net





    1,198,454







    1,206,665



    Other Assets





    295,765







    304,806



    Total Assets



    $

    2,304,648





    $

    2,363,354



    LIABILITIES AND STOCKHOLDERS' EQUITY













    Current Liabilities



    $

    669,034





    $

    607,870



    Deferred Income Taxes





    9,612







    10,373



    Long-term Debt





    332,632







    401,248



    Other Non-current Liabilities





    123,436







    127,373



    Total Stepan Company Stockholders' Equity





    1,169,934







    1,216,490



    Total Liabilities and Stockholders' Equity



    $

    2,304,648





    $

    2,363,354



     

    Selected Balance Sheet Information 



    The Company's total debt decreased by $63.1 million and cash decreased by $47.6 million versus September 30, 2024.  The decrease in debt and cash primarily reflects fourth quarter repayments against the Company's revolving credit facility.  The Company's net debt level decreased $15.5 million versus September 30, 2024 and the net debt ratio remained constant at 31% in the quarter (Net Debt and Net Debt Ratio are non-GAAP measures, reconciliations of which are shown in the table below).  Management uses the non-GAAP net debt metric to show a more complete picture of the Company's overall liquidity, financial flexibility and leverage level. 



    ($ in millions)

    December 31,

    2024





    September 30,

    2024





    June 30,

    2024





    March 31,

    2024





    December 31,

    2023



    Net Debt





























    Total Debt

    $

    625.4





    $

    688.5





    $

    657.1





    $

    646.0





    $

    654.1



    Cash



    99.7







    147.3







    124.7







    125.8







    129.8



    Net Debt

    $

    525.7





    $

    541.2





    $

    532.4





    $

    520.2





    $

    524.3



    Equity



    1,169.9







    1,219.4







    1,192.4







    1,214.5







    1,216.5



    Net Debt + Equity

    $

    1,695.6





    $

    1,760.6





    $

    1,724.8





    $

    1,734.7





    $

    1,740.8



    Net Debt / (Net Debt + Equity)



    31

    %





    31

    %





    31

    %





    30

    %





    30

    %

     

    The major working capital components were:



    ($ in millions)

    December 31,

    2024





    September 30,

    2024





    June 30,

    2024





    March 31,

    2024





    December 31,

    2023



    Net Receivables

    $

    388.0





    $

    434.1





    $

    437.3





    $

    446.6





    $

    422.1



    Inventories



    288.7







    296.7







    266.0







    257.1







    265.6



    Accounts Payable



    (258.8)







    (257.1)







    (251.2)







    (256.9)







    (233.0)





    $

    417.9





    $

    473.7





    $

    452.1





    $

    446.8





    $

    454.7



     

    Table VI



    Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA



    Management uses the non-GAAP EBITDA and adjusted EBITDA metrics to evaluate the Company's operating performance.  Management excludes the items listed in the table below because they are non-operational items.  Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income.







    Three Months Ended

    December 31, 2024



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    16.2





    $

    3.4





    $

    5.6





    $

    (17.5)





    $

    7.7



       Depreciation and Amortization



    $

    18.5





    $

    8.0





    $

    1.5





    $

    0.5





    $

    28.5



       Other, Net Income



    $

    -





    $

    -





    $

    -





    $

    (0.4)





    $

    (0.4)



    EBITDA



























    $

    35.8



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    (1.0)





    $

    (1.0)



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    0.2





    $

    0.2



    Adjusted EBITDA



    $

    34.7





    $

    11.4





    $

    7.1





    $

    (18.2)





    $

    35.0







































    Three Months Ended

    December 31, 2023



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    14.8





    $

    12.6





    $

    2.8





    $

    (30.0)





    $

    0.2



       Depreciation and Amortization



    $

    16.7





    $

    7.9





    $

    1.5





    $

    1.0





    $

    27.1



       Other, Net Income



    $

    -





    $

    -





    $

    -





    $

    (1.5)





    $

    (1.5)



    EBITDA



























    $

    25.8



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    3.0





    $

    3.0



       Cash Settled SARs



    $

    0.1





    $

    -





    $

    -





    $

    -





    $

    0.1



       Goodwill and Other

          Intangibles Impairment



    $

    -





    $

    -





    $

    -





    $

    2.0





    $

    2.0



       Business Restructuring/

          Asset Impairment



    $

    -





    $

    -





    $

    -





    $

    6.1





    $

    6.1



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    0.5





    $

    0.5



    Adjusted EBITDA



    $

    31.6





    $

    20.5





    $

    4.3





    $

    (18.9)





    $

    37.5













    Twelve Months Ended

    December 31, 2024



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    85.6





    $

    40.6





    $

    20.9





    $

    (76.6)





    $

    70.5



       Depreciation and Amortization



    $

    72.0





    $

    32.4





    $

    6.0





    $

    1.9





    $

    112.3



       Other, Net Income



    $

    -





    $

    -





    $

    -





    $

    4.1





    $

    4.1



    EBITDA



























    $

    186.9



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    (2.4)





    $

    (2.4)



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    2.5





    $

    2.5



    Adjusted EBITDA



    $

    157.6





    $

    73.0





    $

    26.9





    $

    (70.5)





    $

    187.0







































    Twelve Months Ended

    December 31, 2023



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    72.4





    $

    60.8





    $

    11.5





    $

    (86.0)





    $

    58.6



       Depreciation and Amortization



    $

    64.4





    $

    32.4





    $

    5.8





    $

    2.7





    $

    105.3



       Other, Net Income (Expense)



    $

    -





    $

    -





    $

    -





    $

    1.9





    $

    1.9



    EBITDA



























    $

    165.8



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    (0.7)





    $

    (0.7)



       Cash Settled SARs



    $

    (0.1)





    $

    -





    $

    -





    $

    -





    $

    (0.1)



       Goodwill and Other

          Intangibles Impairment



    $

    -





    $

    -





    $

    -





    $

    2.0





    $

    2.0



       Business Restructuring/

          Asset Impairment



    $

    -





    $

    -





    $

    -





    $

    12.0





    $

    12.0



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    1.0





    $

    1.0



    Adjusted EBITDA



    $

    136.7





    $

    93.2





    $

    17.3





    $

    (67.2)





    $

    180.0



     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stepan-reports-fourth-quarter-2024-results-302379827.html

    SOURCE Stepan Company

    Get the next $SCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCL

    DatePrice TargetRatingAnalyst
    10/19/2023$89.00Neutral → Buy
    CL King
    3/11/2022$9.00 → $8.00Outperform
    RBC Capital
    12/20/2021$8.50 → $9.00Outperform
    RBC Capital
    More analyst ratings

    $SCL
    Financials

    Live finance-specific insights

    See more
    • Stepan Reports First Quarter 2025 Results

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: First Quarter 2025 Highlights Reported net income was $19.7 million, up 42% versus the prior year. Adjusted net income(1) was $19.3 million, up 32% versus the prior year.EBITDA(2) was $58.0 million and Adjusted EBITDA(2) was $57.5 million, up 16% and 12% respectively, year-over-year.Global sales volume was up 4% year-over-year.Cash from Operations was $6.9 million during the quarter. Free cash flow(3) for the quarter was a negative $25.8 million driven by higher working capital to suppor

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Declares Quarterly Dividend

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.385 per share. The dividend is payable on June 13, 2025, to common stockholders of record on May 30, 2025. The Company increased its quarterly cash dividend in the fourth quarter of 2024 by $0.010 per share, marking the 57th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of specialt

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan to Announce First Quarter 2025 Results on April 29, 2025

      NORTHBROOK, Ill., April 14, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its first quarter 2025 earnings results on Tuesday, April 29, 2025 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 8:00 a.m. ET (7:00 a.m. CT). The call will be hosted by Luis E. Rojo, President and Chief Executive Officer, and Samuel S. Hin

      4/14/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Stepan Company

      SC 13G - STEPAN CO (0000094049) (Subject)

      2/9/24 9:59:18 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Stepan Company (Amendment)

      SC 13G/A - STEPAN CO (0000094049) (Subject)

      1/24/24 12:33:12 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Stepan Company (Amendment)

      SC 13G/A - STEPAN CO (0000094049) (Subject)

      1/22/24 3:52:11 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    SEC Filings

    See more
    • SEC Form SD filed by Stepan Company

      SD - STEPAN CO (0000094049) (Filer)

      5/30/25 5:11:57 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 8-K filed by Stepan Company

      8-K - STEPAN CO (0000094049) (Filer)

      5/21/25 4:31:14 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form SCHEDULE 13G filed by Stepan Company

      SCHEDULE 13G - STEPAN CO (0000094049) (Subject)

      5/13/25 12:17:58 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stepan Announces Agreement to Sell Philippine Assets

      NORTHBROOK, Ill., May 27, 2025 /PRNewswire/ -- Stepan Company (NYSE: SCL) today announced that its subsidiary, Stepan Philippines Quaternaries, Inc. (SPQI), has entered into an agreement to sell SPQI's manufacturing assets located in Bauan, Batangas, Philippines to Masurf, Inc., a subsidiary of Musim Mas Holdings Pte. Ltd. "The sale of this facility aligns with our strategy to focus on core growth areas; our global manufacturing network and the tolling relationship with Masurf after the transaction closes will allow us to continue to service and grow with our broad customer ba

      5/27/25 8:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Reports First Quarter 2025 Results

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: First Quarter 2025 Highlights Reported net income was $19.7 million, up 42% versus the prior year. Adjusted net income(1) was $19.3 million, up 32% versus the prior year.EBITDA(2) was $58.0 million and Adjusted EBITDA(2) was $57.5 million, up 16% and 12% respectively, year-over-year.Global sales volume was up 4% year-over-year.Cash from Operations was $6.9 million during the quarter. Free cash flow(3) for the quarter was a negative $25.8 million driven by higher working capital to suppor

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Declares Quarterly Dividend

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.385 per share. The dividend is payable on June 13, 2025, to common stockholders of record on May 30, 2025. The Company increased its quarterly cash dividend in the fourth quarter of 2024 by $0.010 per share, marking the 57th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of specialt

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stepan Company upgraded by CL King with a new price target

      CL King upgraded Stepan Company from Neutral to Buy and set a new price target of $89.00

      10/19/23 9:02:32 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • RBC Capital reiterated coverage on Shawcor with a new price target

      RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $8.00 from $9.00 previously

      3/11/22 7:14:07 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • RBC Capital reiterated coverage on Shawcor with a new price target

      RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $9.00 from $8.50 previously

      12/20/21 6:55:29 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lewis Susan bought $31,765 worth of shares (500 units at $63.53), increasing direct ownership by 36% to 1,896 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      2/27/25 8:57:39 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • VP GC & Secretary Kabbes David bought $75,388 worth of shares (1,056 units at $71.39) (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      8/15/24 1:19:55 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: EVP, Supply Chain Haire Robert Joseph covered exercise/tax liability with 162 shares, decreasing direct ownership by 22% to 591 units (SEC Form 4)

      4/A - STEPAN CO (0000094049) (Issuer)

      5/21/25 2:56:47 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Stepan F Quinn Jr was granted 2,500 shares, increasing direct ownership by 2% to 105,446 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      5/14/25 6:33:13 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Dearth Randall S. was granted 2,500 shares, increasing direct ownership by 22% to 14,106 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      5/14/25 5:44:33 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Stepan Promotes Luis E. Rojo to President and Chief Executive Officer

      NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today announced the appointment of Luis E. Rojo as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. After a 31-year Stepan career, Scott R. Behrens is departing the Company to pursue other opportunities. "We thank Scott for his leadership and his many contributions to the growth and diversification of Stepan over his career with the Company. During his various roles in R&D, sales and marketing, and leadership, he helped diversify our market presence,

      10/30/24 6:55:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Company Announces Appointment of New Director

      NORTHBROOK, Ill., Feb. 15, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) announced today the appointment of Susan M. Lewis as a Director of Stepan, effective on February 15, 2024. Ms. Lewis spent over 30 years at Dow Inc., a materials science company, and was part of the management team of Corteva, Inc., a global agriculture company, following its spinoff from DowDuPont Inc. Ms. Lewis served as Senior Vice President, Global Operations of Corteva from 2018 until her retirement in 2021, after which she worked as a business and executive consultant through 2023. Ms. Lewis held senior management roles with operations, sustainability and risk management responsibilities and led organizational r

      2/15/24 4:30:00 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an

      6/1/21 4:01:00 PM ET
      $SCL
      $RCEL
      $ANGO
      Package Goods/Cosmetics
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care